MegaRobo
AI-for-Science and laboratory automation platform for drug discovery and industrial inspection.
Website: https://en.megarobo.tech/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | MegaRobo |
| Tagline | AI-for-Science and laboratory automation platform for drug discovery and industrial inspection. |
| Headquarters | Beijing, China [Crunchbase, retrieved 2026] |
| Founded | 2016 [SiliconANGLE, November 2026] |
| Stage | Series D+ [PR Newswire, November 2026] |
| Business model | Hardware + Software |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | East Asia |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) [Edgepedia, retrieved 2026] [LinkedIn, retrieved 2026] |
| Funding label | $100M+ |
| Total disclosed | Approximately $600,000,000 [RobotToday, November 2026] |
Links
Open sources
- Website: https://en.megarobo.tech/
What an Investor Needs First
PUBLIC MegaRobo builds AI-connected laboratory automation and industrial inspection systems, and it merits investor attention now because the company disclosed a nearly $200 million financing in November 2026, bringing reported cumulative funding to roughly $600 million and extending a capital base that few peers in applied AI hardware and scientific infrastructure can match [PR Newswire, November 2026] [RobotToday, November 2026] [DealStreetAsia, November 2026]. Founded in Beijing in 2016, the company has positioned itself around AI-for-Science, with a platform that links models, scientific data, workflows, instruments, robotics, and experimental feedback so software can help design and execute physical experiments rather than only analyze prior results [SiliconANGLE, November 2026] [PR Newswire, November 2026]. That product thesis appears differentiated by scope: MegaRobo is not only selling lab automation into drug discovery workflows, it also reports precision sensing, measurement, and inspection products for semiconductor, optical-interconnect, and display manufacturing, which broadens the commercial surface but also raises execution complexity [Tech Startups, November 2026] [SiliconANGLE, November 2026].
The public record on the founding bench is uneven, but the CEO attribution is relatively clear: multiple sources identify Daniel Huang as founder and chief executive, while other founder names, including Huang Yuqing, Zhang Yan, Qiao Zhixin, Cecilia Cui, and Shawn Dougherty, appear across profile sources with lighter corroboration [SiliconANGLE, November 2026] [Crunchbase, retrieved 2026] [LinkedIn, retrieved 2026] [Edgepedia, retrieved 2026]. Huang's prior operating history spans mophie and other executive roles documented in public profiles, which suggests consumer hardware and company-building experience, though the available sourcing does not yet establish a detailed, independently verified track record in scaled life sciences commercialization [Bloomberg Markets, retrieved 2026] [Forbes, 2013] [The New York Times, 2018]. MegaRobo's business model is best understood as hardware plus software, supported by venture funding from Goldman Sachs Alternatives, Oman Investment Authority, Granite Asia, Asia Investment Capital, CMB International, Sinovation Ventures, and Bosch Ventures, with DealStreetAsia reporting that valuation exceeded $1 billion after the June 2022 Series C [PR Newswire, November 2026] [DealStreetAsia, November 2026] [Crunchbase, retrieved 2026].
For the next 12 to 18 months, the key questions are whether MegaRobo can translate reported reach of more than 500 customers and more than 200 Megalaxy Lab users into durable, referenceable adoption, and whether a company spanning scientific automation and industrial inspection can preserve focus as it scales internationally [PR Newswire, November 2026] [Tech Startups, November 2026] [Oman Observer, November 2026]. Publicly, the setup is promising: large funding support, a category aligned with AI moving from software into physical workflows, and early evidence of customer penetration. The evidence base remains mixed because several core operating metrics and product descriptions still trace back to company statements or lightly corroborated coverage rather than deeply reported independent disclosures [PR Newswire, November 2026] [SiliconANGLE, November 2026] [DealStreetAsia, November 2026].
Claim stands unchecked -- Core funding events are corroborated by multiple public outlets, but several material operating claims in this section, including customer counts and parts of the product scope, rely on company statements or lightly corroborated coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series D+ |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $100M+ total disclosed, approximately $600,000,000 [RobotToday, November 2026] |
Inside the Company
PUBLIC
MegaRobo presents as a Beijing-based deeptech company built around the harder part of AI-for-science, namely connecting software intelligence to instruments, robotics, and physical experimental workflows rather than stopping at data analysis alone [Crunchbase]. The company was founded in 2016 and describes its scope in similarly broad terms on its website, spanning laboratory automation, scientific software, and industrial inspection systems [Crunchbase] [megarobo].
The public record on legal-entity detail is thin in the materials reviewed, so the cleaner chronology rests on what can be corroborated directly. Crunchbase lists MegaRobo as founded in 2016 and headquartered in Beijing, China [Crunchbase]. The company website, retrieved in 2026, describes a team of 150 and says 60% of staff are in R&D, while MegaRobo’s LinkedIn footprint points to a larger organization of more than 300 people, also with 60% in R&D, which suggests growth over time but does not establish when that expansion occurred [megarobo] [LinkedIn].
The clearest public milestones come from financing and category positioning rather than a detailed operating timeline. Crunchbase identifies the company as venture-backed and active in AI, machine learning, robotics, and biotechnology-adjacent workflows [Crunchbase]. On its own site, MegaRobo frames itself as an automation and intelligence infrastructure provider for scientific and industrial use cases, which is consistent with the broader company profile but still company-originated in the absence of state filings in the source set [megarobo].
Partially corroborated -- Confirmed primarily by Crunchbase and the company website, with partial corroboration from LinkedIn on organization scale.
Under the Hood
MIXED
MegaRobo is trying to connect software intelligence to physical lab work, which is the part that matters most here. Public descriptions are fairly consistent on that point: the company says its "One Intelligence Stack" links models and agents with scientific data, workflows, software, instruments, robotics, automation, and real-world feedback so experiments can be designed, executed, and iterated in a machine-readable loop [PR Newswire, November 2026]. Independent coverage describes the same architecture in plainer terms, saying MegaRobo provides software, robotics, and scientific automation that let laboratories run experiments, capture results, and feed outputs into the next stage of analysis [Tech Startups, November 2026].
The laboratory product most often cited is Megalaxy Lab, which has been described as supporting remotely programmable experiments [PR Newswire, November 2026]. That positioning suggests MegaRobo is selling more than a point robot or a single instrument interface. The product surface, as publicly described, is a workflow system that coordinates experiment setup, routing to automated lab systems, execution tracking, and structured result return for another cycle of scientific reasoning [PR Newswire, November 2026].
MegaRobo also appears to have a second product line outside life sciences, and that broadens the technical claim but also complicates the story. Coverage from SiliconANGLE and Tech Startups says the company sells precision sensing, measurement, inspection, and robotics for semiconductor, optical-interconnect, and display manufacturing, where defect diagnosis and yield improvement can carry direct economic value [SiliconANGLE, November 2026] [Tech Startups, November 2026]. One lower-confidence source also describes collaborative robots designed without control boxes or displays, with an emphasis on safety and integration, though that feature set is less well corroborated than the AI-for-Science and inspection narratives [ZoomInfo.com] [PR Newswire, November 2026].
On the evidence available, the technical differentiation rests less on a novel foundation model claim and more on system integration at the boundary between software and hardware. That is a credible wedge if customers value reproducibility, instrument orchestration, and closed-loop experimentation, but the public record still leaves open several diligence points, including which parts of the stack are proprietary, how much of the workflow runs on MegaRobo software versus third-party tools, and whether the same architecture truly serves both drug discovery and industrial inspection at production depth [The Next Web, November 2026] [DealStreetAsia, November 2026].
Partially corroborated -- Core product description is corroborated across PR Newswire, SiliconANGLE, and Tech Startups, but several technical details remain company-led or only partially independently described.
Market Research
PUBLIC
This market matters now because MegaRobo sits at the intersection of two spending pools that are both drawing fresh capital and strategic attention, scientific automation for drug discovery and precision inspection for advanced manufacturing, with the added claim that AI can improve throughput in both settings [SiliconANGLE, November 2026] [Tech Startups, November 2026].
The public record here is thinner than investors would usually want for clean TAM work. No named third-party market report is captured in the source set for AI-for-Science, lab automation, or semiconductor inspection that can support a direct TAM, SAM, or SOM estimate for MegaRobo specifically. What the available reporting does establish is the shape of demand: MegaRobo is selling into buyers that already spend on experimental throughput, data capture, and yield improvement, namely pharmaceutical companies, biotechnology firms, research institutions, and manufacturers in semiconductor, optical-interconnect, and display production [PR Newswire, November 2026] [DealStreetAsia, November 2026] [Tech Startups, November 2026].
That matters because the purchase logic in these environments is usually tied to expensive bottlenecks rather than discretionary software budgets. In drug discovery, the cited coverage frames the company around automating repetitive, high-value workflows such as drug screening, target discovery, and candidate optimization, while routing structured results back into the next experimental cycle [PR Newswire, November 2026] [Tech Startups, November 2026]. In industrial settings, the demand case is tied to defect diagnosis, measurement precision, and yield improvement in semiconductor and display manufacturing, where small process gains can carry direct economic value [Tech Startups, November 2026] [SiliconANGLE, November 2026].
The nearest adjacent markets are therefore not one single category but a stack of overlapping budgets. One sits in laboratory automation and scientific workflow software, where the product claim is to connect AI models, data, instruments, robotics, and automation into a single operating layer for physical experiments [PR Newswire, November 2026]. Another sits in metrology, sensing, and inspection systems for electronics manufacturing, where the company is described as supplying high-precision sensing, measurement, inspection, and robotics rather than pure software [SiliconANGLE, November 2026] [Tech Startups, November 2026]. That split is strategically relevant because hardware-backed categories can be slower to scale, but they may also face lower substitution risk if they become embedded in validated workflows.
Macro and regulatory forces cut both ways. The positive side is straightforward: life sciences labs and advanced manufacturers are both under pressure to shorten development cycles, raise utilization of expensive equipment, and convert operational data into repeatable process improvements, which supports the broader case for automated experimentation and machine-readable outputs [PR Newswire, November 2026] [The Next Web, November 2026]. The caution is that these are regulated or quality-sensitive environments, so adoption can depend on validation, integration, and procurement cycles that are longer than standard enterprise SaaS, especially when the system touches physical instrumentation or production inspection [SiliconANGLE, November 2026] [DealStreetAsia, November 2026].
| Cited market signal | What it indicates | Source |
|---|---|---|
| More than 500 customers across products and technologies | Evidence that the addressable market spans multiple buyer types rather than a single niche, though the figure is company-asserted | [PR Newswire, November 2026] |
| More than 200 Megalaxy Lab customers | Suggests a distinct submarket for remotely programmable laboratory experiments | [PR Newswire, November 2026] |
| Pharmaceutical, biotech, and research institutions named as users | Supports life sciences and research automation as one core demand pool | [PR Newswire, November 2026] [DealStreetAsia, November 2026] |
| Semiconductor, optical-interconnect, and display manufacturing named as target sectors | Supports industrial inspection and measurement as a second core demand pool | [SiliconANGLE, November 2026] [Tech Startups, November 2026] |
The table points to a real, if still loosely bounded, market thesis: MegaRobo is not selling into one monolithic category, but into adjacent workflows where automation can reduce cycle time or improve yield. The missing piece in public sources is third-party market sizing, which means the market case is credible at the category level but still under-documented at the company-specific segmentation level.
Partially corroborated -- Section relies on named public reporting from PR Newswire, SiliconANGLE, DealStreetAsia, The Next Web, and Tech Startups, but no independent third-party market sizing report is present in the captured sources.
Competition and Substitutes
MIXED MegaRobo appears to sit in a crowded but still loosely defined intersection of laboratory automation, AI-for-science software, and industrial inspection, with its positioning broad enough to create option value but broad enough to blur the true peer set as well [PR Newswire, November 2026] [SiliconANGLE, November 2026] [DealStreetAsia, November 2026].
The competitive map breaks into at least three public segments, even though the source set does not name direct rivals. In laboratory automation, the relevant alternatives are incumbent instrument vendors and workflow software providers that already sit inside pharma and research labs, plus newer automation stacks that aim to let software orchestrate physical experiments; MegaRobo's public materials describe a system that links models, data, workflows, instruments, robotics, and feedback into one operating layer, which is a broader claim than a single instrument or a point workflow tool [PR Newswire, November 2026] [Tech Startups, November 2026]. In industrial inspection, the comparison set shifts toward precision sensing and measurement suppliers serving semiconductor, optical-interconnect, and display manufacturing, where purchasing criteria tend to be tied to throughput, defect detection, and yield impact rather than drug discovery productivity [SiliconANGLE, November 2026] [Tech Startups, November 2026].
That creates an unusual form of competitive overlap. A buyer could treat MegaRobo as an automation platform in life sciences, as a hardware and sensing vendor in advanced manufacturing, or as an infrastructure layer for AI-directed experimentation, depending on the use case described in the public reporting [PR Newswire, November 2026] [The Next Web, November 2026]. The advantage is that the company is not forced into a single budget line; the cost is that it likely faces different incumbents, sales motions, and proof requirements in each segment, and the public record does not yet show named customer references that would clarify where it wins most consistently [DealStreetAsia, November 2026] [Oman Observer, November 2026].
Where MegaRobo seems to have a real edge today is capital depth and systems integration. The company has disclosed nearly US$200 million of new financing in November 2026, after a roughly $300 million Series C in June 2022, and cumulative funding has been reported at about $600 million, which matters in categories where product scope spans software, robotics, instruments, and deployment-heavy infrastructure [PR Newswire, November 2026] [DealStreetAsia, November 2026] [RobotToday, November 2026]. Public reporting also repeatedly describes the same integrated architecture, including the "One Intelligence Stack" and the Megalaxy Lab environment for remotely programmable experiments, which suggests the differentiation rests on joining software intelligence to physical execution rather than on the model layer alone [PR Newswire, November 2026] [The Next Web, November 2026] [Tech Startups, November 2026].
That edge is meaningful, but only partly durable on the evidence available. Capital can fund long integration cycles and support a multi-product buildout, and a reported base of more than 500 customers across offerings and more than 200 Megalaxy Lab customers could, if definitions are consistent, improve data flywheel effects and implementation know-how over time [PR Newswire, November 2026] [Tech Startups, November 2026]. Still, those customer figures are company-linked or lightly corroborated in media coverage, and the source set does not name reference accounts, retention data, or proof that the same customer relationship expands from lab automation into industrial inspection, so the durability case remains more plausible than proven [PR Newswire, November 2026] [Oman Observer, November 2026].
The main exposure is strategic sprawl. A company selling into pharmaceutical research, biotech workflows, and semiconductor or display inspection is competing in markets that reward deep vertical specialization, and public coverage does not yet show which wedge is strongest by revenue or deployment density [SiliconANGLE, November 2026] [DealStreetAsia, November 2026]. That leaves MegaRobo exposed to narrower specialists on both ends: life-science automation vendors with established scientific credibility on one side, and inspection incumbents with entrenched manufacturing channels on the other. The public sources do not name those rivals, so it is hard to assign share risk by company, but the risk itself is visible in the breadth of MegaRobo's own positioning [PR Newswire, November 2026] [Tech Startups, November 2026].
Over the next 18 months, the most plausible competitive outcome is not a single category winner but a narrowing of where buyers believe integrated AI-to-experiment systems are credible. MegaRobo is the likely winner if enterprise and research buyers increasingly prefer a unified stack that can route experiments, capture structured results, and feed those results into the next cycle of machine-led reasoning, because that is the capability cluster repeated most consistently across the public reporting [PR Newswire, November 2026] [SiliconANGLE, November 2026]. MegaRobo is the likely loser if procurement in its target markets stays segmented by instrument class and vertical workflow, because in that case broad architecture becomes harder to monetize than point solutions with clearer budget owners and shorter validation cycles [DealStreetAsia, November 2026] [The Next Web, November 2026].
Partially corroborated -- Competitive analysis is grounded in named public reporting on MegaRobo's positioning and product scope, but the source set does not identify named direct competitors or independently verified customer references.
Opportunity
PUBLIC
The prize here is unusually large if execution holds: a company that sits between AI reasoning and physical experimentation could become core infrastructure for both modern drug discovery and selected high-value manufacturing workflows, two budgets where speed, reproducibility, and yield directly affect enterprise economics [PR Newswire, November 2026] [SiliconANGLE, November 2026] [Tech Startups, November 2026].
The headline opportunity is not simply selling more lab robots. It is becoming the operating layer that lets software design, route, execute, and learn from real-world experiments across instruments, robotics, and scientific workflows, while extending that same control architecture into industrial inspection and measurement where defects and throughput have immediate financial consequences [PR Newswire, November 2026] [Tech Startups, November 2026]. That outcome is still conditional, but the public record does show several ingredients already in place: MegaRobo has been operating since 2016, reported a nearly $300 million Series C in June 2022, reported another nearly $200 million financing in November 2026, and has described a platform architecture, the "One Intelligence Stack," that is broader than a single-point automation tool [DealStreetAsia, November 2026] [PR Newswire, November 2026] [RobotToday, November 2026].
The reach claims matter because they suggest the company may already have enough installed workflow exposure to train customer behavior, not just ship equipment. MegaRobo said its technologies have been deployed by more than 500 customers, while its Megalaxy Lab platform reportedly serves more than 200 customers running remotely programmable experiments [PR Newswire, November 2026] [Oman Observer, November 2026] [Tech Startups, November 2026]. Those figures are company-linked and should be treated carefully, but if directionally correct they point to something more valuable than a hardware estate: repeated experimental runs, structured outputs, and customer process embedding.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Scientific operating system | MegaRobo becomes a standard control layer for AI-directed experiments in pharma, biotech, and research labs, with customers buying software, automation, and instrument integration as one stack | Wider adoption of remotely programmable experimentation through Megalaxy Lab and further standardization around the "One Intelligence Stack" architecture [PR Newswire, November 2026] [Tech Startups, November 2026] | The company already positions its system as connecting models, data, workflows, instruments, robotics, and feedback, and it reports more than 200 Megalaxy Lab customers plus more than 500 customers across products [PR Newswire, November 2026] [Tech Startups, November 2026] |
| Dual-market platform | The company turns its life sciences base into one pillar and scales industrial sensing and inspection into a second, creating a diversified deeptech platform rather than a single vertical vendor | Cross-selling of precision sensing, measurement, inspection, and robotics into semiconductor, optical-interconnect, and display customers [SiliconANGLE, November 2026] [Tech Startups, November 2026] | Public coverage consistently describes MegaRobo as operating across both scientific automation and industrial inspection, which is unusual and could widen budget access if execution remains coherent [SiliconANGLE, November 2026] [PR Newswire, November 2026] |
| Capital-backed global expansion | Fresh capital and sovereign-linked support help MegaRobo move from a China-centered leader into a broader international supplier of automated scientific infrastructure | The November 2026 financing led by Oman Investment Authority, with participation from CMB International and existing investors, funds overseas expansion and core technology buildout [PR Newswire, November 2026] [DealStreetAsia, November 2026] | The latest round reportedly brought cumulative funding to about $600 million, giving the company a balance sheet more consistent with infrastructure ambition than with a narrow point-solution vendor [RobotToday, November 2026] [DealStreetAsia, November 2026] |
What compounding looks like is fairly clear in concept, even if the public evidence is still early. Each additional laboratory workflow routed through MegaRobo can generate more structured experimental data, more software-instrument integrations, and more reasons for a customer to standardize future work on the same stack; each additional industrial deployment can deepen process knowledge in inspection-heavy settings where false negatives and yield loss carry visible cost [PR Newswire, November 2026] [SiliconANGLE, November 2026]. If the company is genuinely coordinating models, agents, data, robotics, and feedback in one architecture, then the moat is less about any single robot and more about the accumulated workflow layer that sits between enterprise intent and physical execution [PR Newswire, November 2026].
There is also a distribution angle. A platform that can serve pharmaceutical companies, biotechnology firms, research institutions, and selected manufacturers has more shots on goal than a single-segment laboratory automation supplier, and public reporting suggests MegaRobo is already selling into both scientific and industrial environments [Oman Observer, November 2026] [Tech Startups, November 2026]. That does not guarantee efficient expansion, but it does create the possibility that product improvements in orchestration, sensing, or automation benefit multiple end markets at once.
The size of the win is best framed through scenarios rather than certainty. DealStreetAsia reported that MegaRobo's valuation exceeded $1 billion after its June 2022 Series C round [DealStreetAsia, November 2026]. If the company were to become a durable system-of-record and execution layer for AI-guided experimentation across hundreds of enterprise labs while maintaining its industrial inspection business, a multi-billion-dollar outcome is conceivable from the current base (scenario, not a forecast), particularly because investors have already funded it like a platform company rather than a niche tools vendor [DealStreetAsia, November 2026] [RobotToday, November 2026]. Public materials do not provide enough verified revenue or margin data to anchor a tighter valuation range, so the upside case rests on strategic position: if MegaRobo becomes the layer where software meets the physical world in repeatable scientific workflows, the company could matter far beyond the installed value of its hardware.
Partially corroborated -- This section relies on named public reporting from PR Newswire, DealStreetAsia, SiliconANGLE, Tech Startups, RobotToday, and Oman Observer, but several material operating claims, including customer counts and platform scope, originate with the company or are repeated from company-linked disclosures.
Sources
Open sources
[Crunchbase, retrieved 2026] MegaRobo - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/megarobo
[SiliconANGLE, November 2026] China-based AI robotics biotech firm MegaRobo raises $200M to accelerate scientific discovery | https://siliconangle.com/2026/11/19/china-based-ai-robotics-biotech-firm-megarobo-raises-200m-to-accelerate-scientific-discovery/
[PR Newswire, November 2026] MegaRobo Raises Nearly US$200 Million in New Funding to Build Intelligence Infrastructure for the Physical World | https://www.prnewswire.com/news-releases/megarobo-raises-nearly-us200-million-in-new-funding-to-build-intelligence-infrastructure-for-the-physical-world-302944671.html
[Edgepedia, retrieved 2026] MegaRobo Technologies (镁伽科技) | https://www.edgechat.ai/megarobo-technologies
[LinkedIn, retrieved 2026] Cecilia Cui is Founder of MegaRobo Technologies, Inc. | https://www.linkedin.com/
[RobotToday, November 2026] MegaRobo Raises Nearly $200 Million to Expand AI-Powered Laboratory Automation | https://robottoday.com/industry-briefing/megarobo-raises-nearly-200-million-to-expand-ai-powered-laboratory-automation/18519
[DealStreetAsia, November 2026] Chinese unicorn MegaRobo raises $200m from Oman wealth fund, others | https://www.dealstreetasia.com/stories/chinese-ai4s-unicorn-megarobo-raises-funding-501557
[Tech Startups, November 2026] MegaRobo raises nearly $200M to let AI run real lab experiments | https://techstartups.com/
[Bloomberg Markets, retrieved 2026] Daniel Huang, Mophie Inc: Profile and Biography | https://www.bloomberg.com/profile/person/18004707
[Forbes, 2013] How Mophie Turned A Battery Case Into A $100 Million Business | https://www.forbes.com/
[The New York Times, 2018] Molly Rushing, Daniel Huang | https://www.nytimes.com/2018/11/11/fashion/weddings/molly-rushing-daniel-huang.html
[megarobo, retrieved 2026] megarobo | https://en.megarobo.tech/
[The Next Web, November 2026] MegaRobo raises nearly $200M to let AI run real lab experiments | https://thenextweb.com/news/megarobo-200m-oman-investment-authority-ai-lab-experiments
[ZoomInfo.com, retrieved 2026] MegaRobo Technologies, Inc. | https://www.zoominfo.com/
[Oman Observer, November 2026] MegaRobo raises nearly US$200 million in new funding | https://www.omanobserver.om/
Articles about MegaRobo
- MegaRobo's $600 Million Stack Connects AI to 500 Lab Benches — The Beijing-based unicorn is building a unified platform where AI models can design and execute real-world experiments, a vision backed by nearly $600 million in funding.